Our top pick for
Akers Biosciences, Inc is a medical instruments & supplies business based in the US. Akers Biosciences shares (AKER) are listed on the NASDAQ and all prices are listed in US Dollars. Akers Biosciences employs 12 staff and has a trailing 12-month revenue of around USD$862,026.
Since the stock market crash in March caused by coronavirus, Akers Biosciences's share price has had significant negative movement.
Its last market close was USD$1.94, which is 43.36% down on its pre-crash value of USD$3.425 and 25.16% up on the lowest point reached during the March crash when the shares fell as low as USD$1.55.
If you had bought USD$1,000 worth of Akers Biosciences shares at the start of February 2020, those shares would have been worth USD$647.06 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$633.99.
|Latest market close||USD$1.94|
|52-week range||USD$0.2601 - USD$8.85|
|50-day moving average||USD$2.3335|
|200-day moving average||USD$3.6658|
|Wall St. target price||USD$4|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.715|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-18)||2.65%|
|1 month (2020-10-23)||-12.22%|
|3 months (2020-08-25)||-52.45%|
|6 months (2020-05-22)||-39.56%|
|1 year (2019-11-25)||-72.68%|
|2 years (2018-11-23)||13.45%|
|3 years (2017-11-24)||240.35%|
|5 years (2015-11-25)||-0.51%|
|Gross profit TTM||USD$478,747|
|Return on assets TTM||-43.23%|
|Return on equity TTM||-92.11%|
|Market capitalisation||USD$19.8 million|
TTM: trailing 12 months
There are currently 478,174 Akers Biosciences shares held short by investors – that's known as Akers Biosciences's "short interest". This figure is 18.7% up from 402,839 last month.
There are a few different ways that this level of interest in shorting Akers Biosciences shares can be evaluated.
Akers Biosciences's "short interest ratio" (SIR) is the quantity of Akers Biosciences shares currently shorted divided by the average quantity of Akers Biosciences shares traded daily (recently around 956348). Akers Biosciences's SIR currently stands at 0.5. In other words for every 100,000 Akers Biosciences shares traded daily on the market, roughly 500 shares are currently held short.
However Akers Biosciences's short interest can also be evaluated against the total number of Akers Biosciences shares, or, against the total number of tradable Akers Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Akers Biosciences's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Akers Biosciences shares in existence, roughly 50 shares are currently held short) or 0.0548% of the tradable shares (for every 100,000 tradable Akers Biosciences shares, roughly 55 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Akers Biosciences.
Find out more about how you can short Akers Biosciences stock.
We're not expecting Akers Biosciences to pay a dividend over the next 12 months.
Akers Biosciences's shares were split on a 1:24 basis on 25 November 2019. So if you had owned 24 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Akers Biosciences shares – just the quantity. However, indirectly, the new 2300% higher share price could have impacted the market appetite for Akers Biosciences shares which in turn could have impacted Akers Biosciences's share price.
Over the last 12 months, Akers Biosciences's shares have ranged in value from as little as $0.2601 up to $8.85. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Akers Biosciences's is 0.2344. This would suggest that Akers Biosciences's shares are less volatile than average (for this exchange).
Akers Biosciences, Inc., together with its subsidiaries, develops, produces, and sells rapid screening and testing products designed to deliver medical devices to healthcare providers and consumers in the United States, the People's Republic of China, and internationally. Its products include BreathScan, a disposable breath alcohol detector; PIFA Heparin/PF4 and PIFA PLUSS PF4 rapid tests for Heparin/PF4 antibodies to detect an allergy to the used blood thinner, Heparin; seraSTAT, a rapid blood cell separator; Tri-Cholesterol ?Check', a rapid test for total and high density lipoprotein cholesterol and estimates low density lipo protein; and BreathScan OxiCHek that detects aldehydes or oxidative stress in exhaled human breath. The company was founded in 1989 and is headquartered in Thorofare, New Jersey.
Steps to owning and managing CBAY, with 24-hour and historical pricing before you buy.
Steps to owning and managing CHS, with 24-hour and historical pricing before you buy.
Steps to owning and managing CHAP, with 24-hour and historical pricing before you buy.
Steps to owning and managing CRS, with 24-hour and historical pricing before you buy.
Steps to owning and managing AXLA, with 24-hour and historical pricing before you buy.
Steps to owning and managing ALOT, with 24-hour and historical pricing before you buy.
Steps to owning and managing AMPE, with 24-hour and historical pricing before you buy.
Steps to owning and managing UHAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ALIM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ACU, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.